Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences in New York.

Presentation details:
Event: Stifel 2019 Healthcare Conference
Date: Wednesday, Nov. 20
Time: 2:25 p.m. EST

Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Thursday, Dec. 5
Time: 1:30 p.m. EST

Live and archived audio webcasts of the Stifel and Piper presentations can be accessed by visiting the Investors page of the Protagonist Therapeutics website at

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia and polycythemia vera. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the first half of 2020.

Protagonist is headquartered in Newark, California. For further information, please visit

Cision View original content:

SOURCE Protagonist Therapeutics, Inc.

Company Codes: NASDAQ-NMS:PTGX

Back to news